- Home
- COYA vs TELA Comparison
COYA vs TELA Comparison
Compare COYA & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- TELA
- Stock Information
- Founded
- COYA 2020
- TELA 2012
- Country
- COYA United States
- TELA United States
- Employees
- COYA N/A
- TELA N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- TELA Medical/Dental Instruments
- Sector
- COYA Health Care
- TELA Health Care
- Exchange
- COYA Nasdaq
- TELA Nasdaq
- Market Cap
- COYA 98.5M
- TELA 92.2M
- IPO Year
- COYA 2022
- TELA 2019
- Fundamental
- Price
- COYA $6.48
- TELA $2.24
- Analyst Decision
- COYA Strong Buy
- TELA Strong Buy
- Analyst Count
- COYA 4
- TELA 4
- Target Price
- COYA $16.25
- TELA $9.25
- AVG Volume (30 Days)
- COYA 143.6K
- TELA 152.6K
- Earning Date
- COYA 05-08-2025
- TELA 05-08-2025
- Dividend Yield
- COYA N/A
- TELA N/A
- EPS Growth
- COYA N/A
- TELA N/A
- EPS
- COYA N/A
- TELA N/A
- Revenue
- COYA $9,554,315.00
- TELA $68,649,000.00
- Revenue This Year
- COYA N/A
- TELA $30.39
- Revenue Next Year
- COYA $56.22
- TELA $25.51
- P/E Ratio
- COYA N/A
- TELA N/A
- Revenue Growth
- COYA N/A
- TELA 29.34
- 52 Week Low
- COYA $4.75
- TELA $2.19
- 52 Week High
- COYA $10.69
- TELA $6.50
- Technical
- Relative Strength Index (RSI)
- COYA 49.74
- TELA 30.08
- Support Level
- COYA $6.21
- TELA $2.25
- Resistance Level
- COYA $6.96
- TELA $2.52
- Average True Range (ATR)
- COYA 0.69
- TELA 0.17
- MACD
- COYA -0.03
- TELA -0.02
- Stochastic Oscillator
- COYA 27.16
- TELA 10.09
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About TELA TELA Bio Inc.
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.